Bovie Medical Corporation Announces Appointment of Craig A. Swandal to Board of Directors
March 12 2018 - 4:03PM
Business Wire
Bovie Medical Corporation (NYSEMKT:BVX) (the "Company"),
a maker of medical devices and supplies and the developer of
J-Plasma®, a patented surgical product, today announced the
appointment of Craig A. Swandal to the Company’s Board of
Directors, effective March 9, 2018. Mr. Swandal will also serve as
a member of the Company’s Audit Committee.
“Mr. Swandal has a strong background in global manufacturing
strategy and execution, as well as a track record in leading and
advising companies in the medical technology sector,” said Andrew
Makrides, Chairman of the Company’s Board of Directors. “On behalf
of my fellow directors, I am pleased to welcome Craig Swandal to
our Board and we look forward to leveraging his insights and
expertise.”
Mr. Swandal joins Bovie Medical’s Board with over 30 years of
experience at public and privately-held medical technology and
electronics manufacturing companies. He began his career in 1981 at
Unisys Corporation, a manufacturer of main frame computer systems,
where he held a variety of manufacturing positions of increasing
responsibility. In 1995 he joined Silent Knight, a manufacturer of
industrial fire and security systems, as a Manufacturing Manager
and was promoted to Vice President of Operations.
In 2001, Mr. Swandal joined Gyrus, a manufacturer of surgical
devices, where he was responsible for the company’s manufacturing
operations as Director of Operations and later Vice President of
Operations. During his tenure, he improved manufacturing
efficiencies by leading his manufacturing group through the
implementation of lean and Six Sigma techniques. Following Gyrus’s
acquisition of ACMI in 2005, Mr. Swandal was promoted to Senior
Vice President and was responsible for the global operations of the
combined company, which included 12 facilities across 8 countries.
He developed and executed Gyrus ACMI’s strategy to consolidate its
manufacturing, distribution, customer service and service and
repair operations and was a member of the leadership team that
successfully sold the company to Olympus Corporation for $2.2
billion in 2008.
Following the acquisition of Gyrus ACMI, Mr. Swandal served on
the executive leadership teams of several companies, including ATS
Medical, ACELL and Tendyne, where he was focused on operational
development. He is currently the Principal of Lead 2 Change
Consulting, where he assists companies in identifying and
implementing new manufacturing initiatives. Mr. Swandal holds a
Bachelor’s degree in Organizational Management and Communications
from Concordia University, as well as a mini Master of Business
Administration in Medical Technology from the University of St
Thomas.
About Bovie Medical
Corporation:
Bovie Medical Corporation is a leading maker of medical devices
and supplies as well as the developer of J-Plasma®, a patented
plasma-based surgical product for cutting, coagulation and ablation
of soft tissue. J-Plasma® utilizes a helium ionization process to
produce a stable, focused beam of plasma that provides surgeons
with greater precision, minimal invasiveness and an absence of
conductive currents through the patient during surgery. The
new J-Plasma® handpieces with Cool-Coag™ technology deliver the
precision of helium plasma energy, the power of traditional
monopolar coagulation and the efficiency of plasma beam coagulation
- enabling thin-layer ablation and dissection and fast coagulation
with a single instrument, minimizing instrument exchange and
allowing a surgeon to focus on their patient and their
procedures. With Cool-Coag technology, the new J-Plasma
handpieces can deliver three distinctly different energy
modalities - further increasing the utility and versatility of the
J-Plasma system. Bovie Medical Corporation is also a leader in the
manufacture of a range of electrosurgical products and
technologies, marketed through both private labels and the
Company’s own well-respected brands (Bovie®, IDS™ and DERM™) to
distributors worldwide. The Company also leverages its expertise
through original equipment manufacturing (OEM) agreements with
other medical device manufacturers. For further information about
the Company’s current and new products, please refer to the
Investor Relations section of Bovie Medical Corporation
at www.boviemed.com.
Cautionary Statement on Forward-Looking
Statements:
Certain matters discussed in this release and oral statements
made from time to time by representatives of the Company may
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and the Federal
securities laws. Although the Company believes that the
expectations reflected in such forward-looking statements are based
upon reasonable assumptions, it can give no assurance that its
expectations will be achieved.
Forward-looking information is subject to certain risks, trends
and uncertainties that could cause actual results to differ
materially from those projected. Many of these factors are beyond
the Company's ability to control or predict. Important factors that
may cause actual results to differ materially and that could impact
the Company and the statements contained in this release can be
found in the Company's filings with the Securities and Exchange
Commission including the Company's Report on Form 10-K for the year
ended December 31, 2016 and subsequent Form 10-Q filings. For
forward-looking statements in this release, the Company claims the
protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of
1995.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180312006019/en/
Investor Relations
Contact:Westwicke Partners on behalf of Bovie
Medical CorporationMike Piccinino,
CFA443-213-0500investor.relations@boviemed.com
Bovie (AMEX:BVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bovie (AMEX:BVX)
Historical Stock Chart
From Apr 2023 to Apr 2024